Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

Abstract: A vehicle traction mat in the form of an elongated body member having a top surface with protruding upright gripper members or cleats for engagement by a vehicle wheel or tire includes supplemental openings in the top surface thereof for receiving additional or replacement gripper members and further includes a storage receptacle also located on the top surface for containing various accessories which may be required during use of the device such as cable ties for attaching a plurality of traction mats together to create a roadway, ground spikes for attaching the traction mat to the ground, and the aforementioned additional or replacement gripper members capable of being attached to the top of the traction mat as and when desired.

Abstract: This invention relates to polymeric compositions for application onto natural stone in order to provide for long-term chemical, stain, and water resistance, along with antimicrobial properties. Many natural, unsealed stones do not have stain, etch, or water resistance. The described compositions were developed using a technology of chemical grafting that involves the use of prepolymers, monomers, catalysts, graft initiators, wetting agents, antimicrobial agents, and other ingredients. The composition, when thus applied to the stone surface allows it to obtain a graft polymerization, thereby forming a polymer film that is chemically attached to the natural stone, rather than typical physical bonding of other sealer compositions. The natural stones react with a graft initiator in the composition, which creates the reaction sites on the natural stone surface via free radical mechanisms.

Abstract: Described are a compound of formula (II) or (III): The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.

Abstract: Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.

Abstract: Embodiments of a feed additive delivery device, a system comprising a micro weigh machine and the feed additive delivery device, and a method for using the device and system are disclosed. A particular exemplary feed additive delivery device comprised a feed additive hopper for suppling feed additive to a rotary valve that meters feed additive from the hopper to a blow through assembly having an assembly inlet that receives feed additive from the rotary valve, an assembly outlet through which feed additive is dispensed, and an air port for drawing air into the assembly to facilitate feed additive dispensation through the assembly outlet. The system is useful for batching a composition comprising an animal feed and at least one coated animal feed additive, a delicate animal feed additive, or combinations thereof. For certain embodiments the animals are ruminants and the coated feed additive is a coated methionine product.

Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

Abstract: This invention relates to polymeric compositions for application onto natural stone in order to provide for long-term chemical, stain, and water resistance, along with antimicrobial properties. Many natural, unsealed stones do not have stain, etch, or water resistance. The described compositions were developed using a technology of chemical grafting that involves the use of prepolymers, monomers, catalysts, graft initiators, wetting agents, antimicrobial agents, and other ingredients. The composition, when thus applied to the stone surface allows it to obtain a graft polymerization, thereby forming a polymer film that is chemically attached to the natural stone, rather than typical physical bonding of other sealer compositions. The natural stones react with a graft initiator in the composition, which creates the reaction sites on the natural stone surface via free radical mechanisms.

Abstract: Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimized pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.

Abstract: In one aspect, the invention features, in general, a method of assembling a shaving razor cartridge by providing a housing having a primary guard and a secondary cap. A first blade having a cutting edge is mounted to the housing. A second blade having a cutting edge is mounted to the housing. A bridge member having a pair of spaced apart legs is mounted to the housing immediately between the first blade and the second blade. The first blade, the second blade and the bridge member are secured to the housing with at least one clip.

Abstract: In one aspect, the invention features, in general, a shaving razor cartridge with a housing having a primary guard at a front of the housing, a secondary cap at a rear of the housing and at least one spring member positioned between the primary guard and the secondary cap. A bridge member is positioned between the primary guard and the secondary cap. The bridge member has a primary cap surface and a secondary guard surface. A first blade having a cutting edge is mounted to at least one of the spring members between the primary guard and the primary cap surface. A second blade having a cutting edge is mounted to at least one of the spring members between the secondary guard surface and the secondary cap. The bridge member is mounted on a plurality of the spring members.

Abstract: A shaving cartridge with a housing, having a primary guard at a front of the housing and a secondary cap at a rear of the housing. A bridge member having a primary cap surface and a secondary guard surface is positioned between the primary guard and the secondary cap. A first blade has a cutting edge. The first blade is mounted to the housing between the primary guard and the primary cap surface. A second blade having a cutting edge extending in the same direction as the cutting edge of the first blade is mounted to the housing between the secondary guard surface and the secondary cap. A width of the bridge member is greater than 50% of an interblade span between the cutting edge of the first blade and the cutting edge of the second blade and the interblade span is greater than 3 mm.

Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

Abstract: A fob for a key chain, lanyard, or the like, supports a razor blade, or other knife blade suitable for cutting through relatively thin articles. The razor blade is embedded within the interior of a substantially rectangular-shaped molded plastic housing or casing defining the fob casing. The fob casing includes a slot intercepting one short side and the razor blade embedded inside the fob casing is positioned so that its sharpened blade edge intercepts the slot at an angle a distance from the mouth or opening of the slot. A suitable opening is included in the fob casing to support a key ring, lanyard, or other supporting axillary device.

Abstract: Described are a compound of formula (II) or (III): The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.

Abstract: Described are a compound of formula (II) or (III): The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.

Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

Abstract: The invention relates to compounds of general formula (I): wherein: each of R1 and R9 is independently selected from: —H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl; and wherein: each of RA and RB is independently selected from: C1-4alkyl, halogenated C1-4alkyl, and C6-10aryl; or RA and RB are linked to form a group selected from: C1-6 alkylene and C6-10 arylene; and pharmaceutically acceptable salts thereof, which are useful in the treatment of, for example, Alzheimer's disease. In other aspects the invention also relates to novel formulations of 3,7-diamino-10H-phenothiazinium salts.

Abstract: Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.

Abstract: Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.